Can a Biopsy Spread Cancer? Understanding Tumour Seeding, Risk, and Informed Consent
Few words in cancer care carry as much emotional weight as biopsy. For some, it sounds routine — a necessary step, a box to tick, a means of getting answers. For others, it brings a wave of fear that is harder to name. Not just fear of the result, but fear of the procedure itself. Fear that piercing a tumour might disturb it. Fear that something meant to clarify the picture might, in some way, worsen it.
These fears are often dismissed too quickly. Patients are reassured, sometimes correctly, that biopsy is standard, that the benefits usually outweigh the risks, and that without tissue, diagnosis and treatment planning can be compromised. All of that may be true. But what is also true — and what patients deserve to know — is that tumour cell displacement or seeding after biopsy is a real phenomenon. It is documented in the literature, it is biologically plausible, and it is not irrational for patients to ask about it.
That does not mean biopsy should be feared categorically, or refused reflexively. It does mean the conversation should be more mature than it often is.
The problem in modern cancer care is not simply that procedures carry risk. The deeper problem is that risk is too often discussed in a shallow, one-dimensional way. Patients are told that a biopsy is “necessary” or “low risk,” but rarely are they invited into a nuanced conversation about which risks matter, how often they occur, what makes them more or less likely, and what can be done to minimise them. When those conversations do not happen, fear fills the vacuum. And fear, when left unaddressed, tends to either paralyse people or push them into extreme positions.
What patients usually need is not less truth. They need better truth.
The literature on tumour seeding makes one thing clear: this is not an all-or-nothing issue. Needle-track seeding and tumour cell displacement have been reported across multiple tumour types and specialties. A 2014 review specifically examining biopsy and aspiration described tumour seeding as a recognised risk, with reports most commonly involving breast and liver malignancies in that review’s case set. A more recent 2024 systematic review across specialties likewise confirmed that iatrogenic tumour seeding is documented across a wide range of procedures and instruments, with needle biopsy among the most frequently implicated categories in reported cases.
But the existence of a risk is not the same thing as a universal threat. That distinction matters enormously.
The real clinical question is not: Can biopsy ever seed tumour cells?
The answer to that is clearly yes.
The more useful question is: How relevant is that risk in this tumour type, with this route, using this technique, followed by this treatment plan?
When we ask that question, the picture becomes more measured. In breast biopsy, for example, a recent review concluded that needle-biopsy-induced cancer cell displacement is common, but its clinical significance is more nuanced. It may increase the odds of local recurrence in some contexts, particularly where whole-breast radiation is omitted, but available evidence does not show an impact on regional recurrence or long-term survival overall. That same review concluded that technical modifications of biopsy technique can reduce the risk of displacement and its consequences.
In prostate cancer, the literature suggests the incidence of needle-tract seeding is rare, with review data estimating it at under 1%, though the true incidence remains difficult to quantify.
In head and neck masses, a 2016 review found that seeding after fine-needle aspiration or core biopsy appears extremely low, especially when judged by clinically meaningful tumour development rather than displaced cells alone.
So the honest answer is neither “this never happens” nor “biopsies spread cancer.” The honest answer is more grown-up than that. It is this:
Biopsy-related seeding is real, but context-dependent.
Its significance varies by tumour type, biopsy route, technique, and what definitive treatment follows.
That is precisely why informed consent should be a conversation, not a script.
One of the most valuable things a patient can do is ask better questions before a biopsy. Not hostile questions. Not fear-driven questions. Just intelligent ones. Questions that invite the treating team to move beyond reassurance and into specificity.
Questions such as:
Is this biopsy essential for diagnosis or treatment planning in my case?
What is the known risk of tumour cell displacement or tract seeding with this tumour type and biopsy route?
Is there a difference in risk between fine-needle aspiration, core needle biopsy, and surgical biopsy here?
Will the biopsy tract be removed during surgery, or sterilised within the planned radiation field?
Are there procedural techniques you use to reduce the risk?
Is there any less invasive way to get the information we need?
These questions do not make a patient difficult. They make a patient informed.
They also tend to reveal something important: the quality of communication in the room.
One of the recurring themes in oncology is that patients are often expected to surrender to the process before they fully understand it. This is one of the reasons I wrote Your Oncologist Is Not Your Enemy — not because oncologists are untrustworthy, but because meaningful outcomes are improved when communication becomes clearer, more collaborative, and more honest. Patients should not have to choose between fear and blind trust. There is a third path: informed partnership.
There are also procedural realities that deserve attention. The best-supported ways to reduce biopsy-related seeding risk are technical, not supplement-based. In breast biopsy, for example, recent literature points to technique modifications that can reduce displacement risk and potentially lower local recurrence risk in appropriate contexts. Whether the tract will later be excised or included in a radiation field also matters.
This is why the most evidence-based risk-reduction strategy begins with the procedure itself:
the route chosen,
the instrument used,
the operator’s technique,
and how the tract is managed afterward.
That may not be as exciting as a supplement recommendation, but it is where the strongest evidence currently sits.
This brings us to the more delicate question: Is there any evidence that complementary or alternative medicine reduces biopsy-related seeding?
At present, the answer is no — not directly.
There is currently no strong clinical evidence showing that supplements, herbs, or other complementary therapies specifically prevent tumour seeding after biopsy. To claim otherwise would go beyond the data. Complementary therapies may help manage the effects of cancer and its treatments, and can be used alongside standard care, but they should not be represented as proven anti-seeding interventions when that evidence does not exist.
That said, this is not the same as saying integrative support has no place around a biopsy.
It simply means we need to be precise about what we are and are not claiming.
An integrative approach may still support the broader terrain around any invasive procedure: reducing inflammatory burden, improving metabolic stability, supporting immune competence, regulating sympathetic overdrive, and helping the body recover more coherently from the stress of intervention. That is a very different claim from saying these therapies have been proven to prevent seeding. They have not. But they may still matter for peri-procedural resilience and for the broader biological environment in which cancer exists.
That distinction is critical.
It protects the patient from false certainty.
And it protects integrative care from overpromising.
Liquid biopsy is another area patients often ask about. It is appealing for obvious reasons: it is minimally invasive and avoids physically traversing a tumour. The field is advancing rapidly, and liquid biopsy has real clinical value in selected contexts, particularly for molecular profiling and monitoring. But for most solid tumours, it still does not fully replace tissue diagnosis. It is better understood at present as an important adjunct or alternative in selected scenarios, not a universal substitute.
So where does this leave the patient?
In a better place than either extreme.
Not in the dark, and not in panic.
Not naively reassured, and not catastrophising.
But informed.
Biopsy is often necessary. It often changes management. It often provides information that cannot be obtained in another way. But patients deserve to know that procedural risk is not imaginary, that risk varies, and that the best way to reduce it begins with good questions, good technique, and good communication.
This is the deeper issue beneath biopsy seeding: not just whether it can happen, but whether medicine is willing to have adult conversations about the trade-offs involved.
My view is simple. Patients do not need to be shielded from nuance. They need to be supported through it.
And if there is a complementary role to play here, it is this: to help patients regulate fear, ask better questions, strengthen the terrain around the procedure, and move through the process with more agency than panic.
Because the goal in cancer care is not to avoid every difficult decision.
It is to make those decisions with open eyes, steady hands, and the clearest understanding possible.
.
.
Medical Disclaimer
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider before making any decisions about your cancer treatment, including dietary changes, metabolic strategies, repurposed medications, or integrative therapies.
Every individual’s medical condition is unique, and what works for one person may not be appropriate for another. Integrating metabolic and conventional oncology approaches should be done under the supervision of a highly experienced health professional who understands the complexity of cancer care and the potential interactions between different treatments.
No guarantees of outcome are expressed or implied, and reliance on any information provided in this article is at your own discretion and risk.
References
Svastics E, Chintamani, Bansal A, et al. Risk of tumor cell seeding through biopsy and aspiration. Journal of Pharmacy and Bioallied Sciences. 2014;6(Suppl 1):S5–S9.
Holmes DR. Reducing the risk of needle tract seeding or tumor cell dissemination during needle biopsy procedures. Cancers (Basel). 2024;16(2):317.
Volanis D, Neal DE, Warren AY, et al. Incidence of needle-tract seeding following prostate biopsy for suspected cancer: a review of the literature. BJU International. 2015;115(5):698–704.
Siddiqui F, Chitguppi C, Chandra R, et al. Tumour seeding after fine-needle aspiration and core biopsy of the head and neck: a systematic review. Oral Oncology. 2016;58:42–51.
Gigli S, Della Corte C, Bianchi G, et al. Tumor seeding across specialties: a systematic review. Frontiers in Oncology. 2024;14:1464767.
Cancer Australia. Complementary and alternative therapies. Cancer Australia Position Statement. Available at: https://www.canceraustralia.gov.au/resources/position-statements/complementary-and-alternative-therapies
Pecoraro M, Roca E, Pistone G, et al. Liquid biopsies: emerging role and clinical applications in solid tumours. Cancers (Basel). 2023;15(10):2718.